Targeting the YAP1/TAZ-TEAD Transcriptional Axis Reveals a Therapeutic Vulnerability in Androgen Receptor Signaling Inhibitor (ARSI)-Resistant Prostate Cancer

Therapeutic resistance remains a major barrier in advanced prostate cancer (PCa), particularly after prolonged treatment with second-generation androgen receptor signaling inhibitors (ARSIs) such as enzalutamide. Tumors can evade these drugs by escaping androgen receptor (AR) dependence through cellular plasticity and lineage transitions, but alternative resistance networks remain poorly understood. Enzalutamide-resistant (ENZ-R) PCa cells showed marked activation and nuclear enrichment of the YAP-1/TAZ-TEAD complex. Disrupting this transcriptional interface with CA3 shows strong anti-metastatic effects, inhibiting migration, invasion, and colony formation across AR-dependent and AR-independent PCa cell lines, suggesting efficacy regardless of cellular lineage or AR status. Similar effects with GNE-7883, K-975, and siRNA knockdown supported a class effect. In vivo, CA3 treatment substantially reduces tumor burden in PC3 and DU145 xenograft models, supporting the systemic efficacy of disrupting the YAP-1/TAZ-TEAD axis in aggressive, AR-independent disease. Mechanistically, this anti-tumor response is driven by potent cytotoxicity: CA3 induces substantial DNA damage and apoptosis in both in vitro and in vivo settings. Moreover, we identified increased YAP-1/WWTR1(Taz) expression as a negative predictor of therapeutic response in PCa patients. These findings indicate that enzalutamide resistance creates a targetable dependence on functional Hippo transcription. Small-molecule disruption of YAP-1/TAZ-TEAD may offer a rational strategy to counter treatment resistance and lineage escape in advanced PCa.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-20
DOI
https://doi.org/10.64898/2026.11.19.767854
Primary Topic
Hippo pathway signaling and YAP/TAZ
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Targeting the YAP1/TAZ-TEAD Transcriptional Axis Reveals a Therapeutic Vulnerability in Androgen Receptor Signaling Inhibitor (ARSI)-Resistant Prostate Cancer

Guobin Kang, Dorota Danuta Wyczechowska, Santosh Lamichhane, Hari K. Koul et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Hippo pathway signaling and YAP/TAZ
preprint

Targeting the YAP1/TAZ-TEAD Transcriptional Axis Reveals a Therapeutic Vulnerability in Androgen Receptor Signaling Inhibitor (ARSI)-Resistant Prostate Cancer

Guobin Kang, Dorota Danuta Wyczechowska, Santosh Lamichhane, Hari K. Koul, Vandana Mohan, Praveen Kumar Jaiswal, Sweaty Koul
preprint en

Abstract

Therapeutic resistance remains a major barrier in advanced prostate cancer (PCa), particularly after prolonged treatment with second-generation androgen receptor signaling inhibitors (ARSIs) such as enzalutamide. Tumors can evade these drugs by escaping androgen receptor (AR) dependence through cellular plasticity and lineage transitions, but alternative resistance networks remain poorly understood. Enzalutamide-resistant (ENZ-R) PCa cells showed marked activation and nuclear enrichment of the YAP-1/TAZ-TEAD complex. Disrupting this transcriptional interface with CA3 shows strong anti-metastatic effects, inhibiting migration, invasion, and colony formation across AR-dependent and AR-independent PCa cell lines, suggesting efficacy regardless of cellular lineage or AR status. Similar effects with GNE-7883, K-975, and siRNA knockdown supported a class effect. In vivo, CA3 treatment substantially reduces tumor burden in PC3 and DU145 xenograft models, supporting the systemic efficacy of disrupting the YAP-1/TAZ-TEAD axis in aggressive, AR-independent disease. Mechanistically, this anti-tumor response is driven by potent cytotoxicity: CA3 induces substantial DNA damage and apoptosis in both in vitro and in vivo settings. Moreover, we identified increased YAP-1/WWTR1(Taz) expression as a negative predictor of therapeutic response in PCa patients. These findings indicate that enzalutamide resistance creates a targetable dependence on functional Hippo transcription. Small-molecule disruption of YAP-1/TAZ-TEAD may offer a rational strategy to counter treatment resistance and lineage escape in advanced PCa.

bioRxiv (Cold Spring Harbor Laboratory)
Louisiana State University Health Sciences Center New Orleans (US), The University of Texas Southwestern Medical Center (US)
U.S. Department of Veterans Affairs, National Institutes of Health, National Cancer Institute
Good health and well-being
Hippo pathway signaling and YAP/TAZ
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon